Frontiers in Pharmacology (Aug 2024)

Angong Niuhuang Wan ameliorates LPS-induced cerebrovascular edema by inhibiting blood‒brain barrier leakage and promoting the membrane expression of AQP4

  • Bo-Tong Liu,
  • Bo-Tong Liu,
  • Bo-Tong Liu,
  • Bo-Tong Liu,
  • Bo-Tong Liu,
  • Quan Li,
  • Quan Li,
  • Quan Li,
  • Quan Li,
  • Kai Sun,
  • Kai Sun,
  • Kai Sun,
  • Kai Sun,
  • Chun-Shui Pan,
  • Chun-Shui Pan,
  • Chun-Shui Pan,
  • Chun-Shui Pan,
  • Xin-Mei Huo,
  • Xin-Mei Huo,
  • Xin-Mei Huo,
  • Xin-Mei Huo,
  • Xin-Mei Huo,
  • Ping Huang,
  • Ping Huang,
  • Ping Huang,
  • Ping Huang,
  • Li Yan,
  • Li Yan,
  • Li Yan,
  • Li Yan,
  • Qi-Hua He,
  • Li-Jun Zhong,
  • Yuan Wang,
  • Meng-Lei Hu,
  • Meng-Lei Hu,
  • Meng-Lei Hu,
  • Meng-Lei Hu,
  • Meng-Lei Hu,
  • An-Qing Li,
  • An-Qing Li,
  • An-Qing Li,
  • An-Qing Li,
  • An-Qing Li,
  • Ying-Qian Jiao,
  • Ying-Qian Jiao,
  • Ying-Qian Jiao,
  • Ying-Qian Jiao,
  • Ying-Qian Jiao,
  • Shuang Zhang,
  • Shuang Zhang,
  • Shuang Zhang,
  • Shuang Zhang,
  • Shuang Zhang,
  • Xiao-Yi Wang,
  • Xiao-Yi Wang,
  • Xiao-Yi Wang,
  • Xiao-Yi Wang,
  • Xiao-Yi Wang,
  • Jian Liu,
  • Jian Liu,
  • Jian Liu,
  • Jian Liu,
  • Jian Liu,
  • Jing-Yan Han,
  • Jing-Yan Han,
  • Jing-Yan Han,
  • Jing-Yan Han,
  • Jing-Yan Han

DOI
https://doi.org/10.3389/fphar.2024.1421635
Journal volume & issue
Vol. 15

Abstract

Read online

IntroductionAngong Niuhuang Wan (AGNHW), developed during the Qing dynasty (18th century) for the treatment of consciousness disturbances caused by severe infections, has been used to treat brain edema caused by ischemia‒reperfusion. However, it remains unclear whether AGNHW can ameliorate vascular-origin brain edema caused by lipopolysaccharides (LPS). This study explored the ameliorative effects of AGNHW on LPS-induced cerebrovascular edema in mice, as well as the potential underlying mechanisms.MethodsA cerebrovascular edema model was established in male C57BL/6N mice by two intraperitoneal injections of LPS (15 mg/kg), at 0 and 24 h. AGNHW was administered by gavage at doses of 0.2275 g/kg, 0.455 g/kg, and 0.91 g/kg, 2 h after LPS administration. In control mice, normal saline (NS) or AGNHW (0.455 g/kg) was administered by gavage 2 h after intraperitoneal injection of NS. The survival rate, cerebral water content, cerebral venous FITC-dextran leakage, Evans blue extravasation, and expression of vascular endothelial cadherin (VE-cadherin), zonula occludens-1 (ZO-1), claudin-5, phosphorylated caveolin-1 (CAV-1), and cytomembrane and cytoplasmic aquaporin 1 (AQP1) and aquaporin 4 (AQP4) were evaluated. The cerebral tissue phosphoproteome, blood levels of AGNHW metabolites, and the relationships between these blood metabolites and differentially phosphorylated proteins were analyzed.ResultsAGNHW inhibited the LPS-induced decrease in survival rate, increase in cerebral water content, decrease in VE-Cadherin expression and increase in phosphorylated CAV-1 (P-CAV-1). AGNHW treatment increased the expression of AQP4 on astrocyte membrane after LPS injection. AGNHW also inhibited the LPS-induced increases in the phosphorylation of 21 proteins, including protein kinase C-α (PKC-α) and mitogen-activated protein kinase 1 (MAPK1), in the cerebral tissue. Eleven AGNHW metabolites were detected in the blood. These metabolites might exert therapeutic effects by regulating PKC-α and MAPK1.ConclusionAGNHW can ameliorate cerebrovascular edema caused by LPS. This effect is associated with the inhibition of VE-Cadherin reduction and CAV-1 phosphorylation, as well as the upregulation of AQP4 expression on the astrocyte membrane, following LPS injection.

Keywords